Akero
Sean Doyle is an accomplished Senior Director of Information Technology and Operations at Akero Therapeutics, with extensive experience in IT infrastructure and operations across various pharmaceutical and technology companies. Previously, Sean served as Senior Director of Information Technology at Lyell Immunopharma, where responsibilities included managing a $10 million IT budget and overseeing compliance during the company's growth and IPO. At Achaogen, Sean played a pivotal role in executing a technology roadmap that supported significant growth and product launch, while earlier positions included management roles at Northland Control Systems, Applied Materials, Genentech, and FedEx, showcasing a strong background in service delivery and operational excellence. Sean holds a Bachelor’s degree in Economics from Virginia Tech.
This person is not in any teams
This person is not in any offices
Akero
1 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.